Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function.
The global Sarcopenia Therapeutic market is projected to reach US$ 3670 million in 2029, increasing from US$ 2762.8 million in 2022, with the CAGR of 4.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sarcopenia Therapeutic market research.
The Sarcopenia Supplement market is primarily driven by the aging global population and the increasing awareness of age-related muscle loss. Sarcopenia supplements, designed to support muscle health and prevent muscle deterioration, cater to the growing demand for proactive approaches to healthy aging. The desire to maintain mobility, independence, and overall quality of life among the elderly population contributes to market growth. However, challenges include the need for well-researched and evidence-based formulations that effectively address muscle loss. Navigating regulatory requirements and ensuring consumer trust in supplement efficacy are ongoing concerns. Moreover, the market faces competition from various dietary and lifestyle interventions for muscle health. The market's success hinges on scientific advancements in supplement formulation, rigorous clinical testing, and educational efforts to inform both consumers and healthcare professionals about the benefits and appropriate use of sarcopenia supplements.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sarcopenia Therapeutic market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Abbott Laboratories
狈别蝉迟濒茅
Pfizer
Amway
By-health
Usana
A&Z Pharmaceutical
GlaxoSmithKline
Bayer
H&H
Blackmores
Zhendong Group
Segment by Type
Protein Supplement
Calcium Supplement
Other
Segment by Application
Online Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Sarcopenia Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Sarcopenia Therapeutic 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Protein Supplement
1.2.3 Calcium Supplement
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global Sarcopenia Therapeutic 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Online Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sarcopenia Therapeutic 麻豆原创 Perspective (2018-2029)
2.2 Sarcopenia Therapeutic Growth Trends by Region
2.2.1 Global Sarcopenia Therapeutic 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Sarcopenia Therapeutic Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Sarcopenia Therapeutic Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Sarcopenia Therapeutic 麻豆原创 Dynamics
2.3.1 Sarcopenia Therapeutic Industry Trends
2.3.2 Sarcopenia Therapeutic 麻豆原创 Drivers
2.3.3 Sarcopenia Therapeutic 麻豆原创 Challenges
2.3.4 Sarcopenia Therapeutic 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sarcopenia Therapeutic Players by Revenue
3.1.1 Global Top Sarcopenia Therapeutic Players by Revenue (2018-2023)
3.1.2 Global Sarcopenia Therapeutic Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Sarcopenia Therapeutic 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sarcopenia Therapeutic Revenue
3.4 Global Sarcopenia Therapeutic 麻豆原创 Concentration Ratio
3.4.1 Global Sarcopenia Therapeutic 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sarcopenia Therapeutic Revenue in 2022
3.5 Sarcopenia Therapeutic Key Players Head office and Area Served
3.6 Key Players Sarcopenia Therapeutic Product Solution and Service
3.7 Date of Enter into Sarcopenia Therapeutic 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Sarcopenia Therapeutic Breakdown Data by Type
4.1 Global Sarcopenia Therapeutic Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Sarcopenia Therapeutic Forecasted 麻豆原创 Size by Type (2024-2029)
5 Sarcopenia Therapeutic Breakdown Data by Application
5.1 Global Sarcopenia Therapeutic Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Sarcopenia Therapeutic Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Sarcopenia Therapeutic 麻豆原创 Size (2018-2029)
6.2 North America Sarcopenia Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Sarcopenia Therapeutic 麻豆原创 Size by Country (2018-2023)
6.4 North America Sarcopenia Therapeutic 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sarcopenia Therapeutic 麻豆原创 Size (2018-2029)
7.2 Europe Sarcopenia Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Sarcopenia Therapeutic 麻豆原创 Size by Country (2018-2023)
7.4 Europe Sarcopenia Therapeutic 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sarcopenia Therapeutic 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Sarcopenia Therapeutic 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Sarcopenia Therapeutic 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Sarcopenia Therapeutic 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sarcopenia Therapeutic 麻豆原创 Size (2018-2029)
9.2 Latin America Sarcopenia Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Sarcopenia Therapeutic 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Sarcopenia Therapeutic 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sarcopenia Therapeutic 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Sarcopenia Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Sarcopenia Therapeutic 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Sarcopenia Therapeutic 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Sarcopenia Therapeutic Introduction
11.1.4 Abbott Laboratories Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 狈别蝉迟濒茅
11.2.1 狈别蝉迟濒茅 Company Detail
11.2.2 狈别蝉迟濒茅 Business Overview
11.2.3 狈别蝉迟濒茅 Sarcopenia Therapeutic Introduction
11.2.4 狈别蝉迟濒茅 Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.2.5 狈别蝉迟濒茅 Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Sarcopenia Therapeutic Introduction
11.3.4 Pfizer Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Amway
11.4.1 Amway Company Detail
11.4.2 Amway Business Overview
11.4.3 Amway Sarcopenia Therapeutic Introduction
11.4.4 Amway Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.4.5 Amway Recent Development
11.5 By-health
11.5.1 By-health Company Detail
11.5.2 By-health Business Overview
11.5.3 By-health Sarcopenia Therapeutic Introduction
11.5.4 By-health Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.5.5 By-health Recent Development
11.6 Usana
11.6.1 Usana Company Detail
11.6.2 Usana Business Overview
11.6.3 Usana Sarcopenia Therapeutic Introduction
11.6.4 Usana Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.6.5 Usana Recent Development
11.7 A&Z Pharmaceutical
11.7.1 A&Z Pharmaceutical Company Detail
11.7.2 A&Z Pharmaceutical Business Overview
11.7.3 A&Z Pharmaceutical Sarcopenia Therapeutic Introduction
11.7.4 A&Z Pharmaceutical Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.7.5 A&Z Pharmaceutical Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Sarcopenia Therapeutic Introduction
11.8.4 GlaxoSmithKline Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.8.5 GlaxoSmithKline Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Sarcopenia Therapeutic Introduction
11.9.4 Bayer Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.9.5 Bayer Recent Development
11.10 H&H
11.10.1 H&H Company Detail
11.10.2 H&H Business Overview
11.10.3 H&H Sarcopenia Therapeutic Introduction
11.10.4 H&H Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.10.5 H&H Recent Development
11.11 Blackmores
11.11.1 Blackmores Company Detail
11.11.2 Blackmores Business Overview
11.11.3 Blackmores Sarcopenia Therapeutic Introduction
11.11.4 Blackmores Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.11.5 Blackmores Recent Development
11.12 Zhendong Group
11.12.1 Zhendong Group Company Detail
11.12.2 Zhendong Group Business Overview
11.12.3 Zhendong Group Sarcopenia Therapeutic Introduction
11.12.4 Zhendong Group Revenue in Sarcopenia Therapeutic Business (2018-2023)
11.12.5 Zhendong Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott Laboratories
狈别蝉迟濒茅
Pfizer
Amway
By-health
Usana
A&Z Pharmaceutical
GlaxoSmithKline
Bayer
H&H
Blackmores
Zhendong Group
听
听
*If Applicable.